Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMJBHO0)

Drug Name
PC-DAC:Insulin Drug Info
Synonyms
Capsulin; Intesulin; Macrulin; Nodlin; SuliXen; AERx Diabetes Management System; AERx iDMS; Capsulin IR; Capsulin OAD; Capsulin insulin replacement; Insulin tregopil; Ultrafast Insulin program; HIM2; AERx (insulin); AT-1391; AT-2391; Analog-PH20; CADDYS (insulin); CJC-1530; CJC-1531; CJC-1575; CJC-1576; Capsulin oral anti-diabetic; DTY-001; GW-843362; GW-843362M; Hexyl insulin monoconjugate, Nobex; IN-105; Inhaled insulin, Andaris; Insulin-PH20; Intesulin-1; Intesulin-IVE; NB-058; NIN-058; NN-1998; ORMD-0801; Oral insulin, Emisphere; Oral insulin, Nobex; PC-Insulin; Inhaled insulin, QDose/BMS; Inhaled insulin, Quadrant/MicroDose; Insulin (inhaled), Aradigm; Insulin (inhaled), QDose; Insulin (inhaled),Translational Research; Insulin (oral), Biocon; Insulin (oral), Coremed; Insulin (oral), Protein Delivery Inc; Insulin (pulmonary), Translational Research; MicroPor (insulin), Altea
Indication
Disease Entry ICD 11 Status REF
Type-1 diabetes 5A10 Phase 3 [1]
Type-2 diabetes 5A11 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMJBHO0

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Insulin (INS) TTZOPHG INS_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Insulin (INS) DTT INS 0.848 2.138 0.379 0.926
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Type-1 diabetes
ICD Disease Classification 5A10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Insulin (INS) DTT INS 6.70E-01 -0.12 -0.46
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00411892) Effect of Inhaled Insulin (AERx iDMS) on Blood Glucose Control in Type 2 Diabetes. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Development and Testing of Solid Dose Formulations Containing Polysialic Acid Insulin Conjugate: Next Generation of Long-Acting Insulin. J Diabetes Sci Technol. 2010 May; 4(3): 532-539.